Introduction
Hematopoietic stem cells (HSCs) have ability to self renew while functionally repopulating the cells of the blood and lymph for the life of an individual. These cells are thought to retain a high capacity for plasticity that would contribute to their ability to differentiate into not only hematopoietic cells but also non-hematopoietic tissues such as brain, heart, skeletal muscle, liver and endothelial cells, following injury or stress (Heike et al., 2004) . Such capacity of these cells gives rise to the hope that hematopoietic stem cells may regenerate various damaged tissues. In that regard, ex vivo expansion of hematopoietic stem cells is a promising technology for many potential applications from marrow reconstitution to gene therapy. Despite of considerable progresses gained during the past ten years in understanding the biology of hematopoietic stem cells and its ex vivo expansion, the success was limited (Piacibello et al., 1997; Shih et al., 1999; Lewis et al., 2001) . Self-renewal of stem cells depends on several critical factors, including the hematopoietic microenvironment, interactions with supporting stromal cells (Charbord, 2001) , features of the extracellular matrix (W illiams et al., 1991) , hematopoietic growth factors (Feugier et al., 2002; Terada et al., 2003) and cytokines (Flores-Guzman et al., 2002) .
Leukotriene B4 (LTB4), derived from arachidonic acid, is a potent chemotactic agent and activating factor for hematopoietic cells. Until recently, two cell surface receptors for LTB4 have been identified; BLT1, a high affinity receptor, and BLT2, a low-affinity receptor. BLT2 is expressed ubiquitously, in contrast to BLT1 expressed predominantly in leukocytes. The differences in the distribution and pharmacological characteristics of BLT1 and BLT2 suggest distinct role(s) for these receptors in vivo (Toda et al., 2002) . Based on the previous observations, LTB4 seems to play important roles in inflammation in addition to host defense in vivo (S.W. Crooks et al., 1998) . Recently, it has been reported that cysteinyl leukotriene receptor is involved in differentiation of HSCs into eosinophils (Hashida et al., 2001) . In addition, several eicosanoids have been reported to be involved in stem cell differentiation or proliferation (Desplat et al., 2000; Braccioni et al., 2002) . In this study, we have investigated the effect of LTB4, one of the potent lipid mediators, on cell proliferation, differentiation, and self-renewal capacity during the long-term culture of HSCs.
Leukotriene B 4 pathway regulates the fate of the hematopoietic stem cells

M aterials and M ethods
Cell source and CD34 + cell purification
Umbilical cord blood was obtained at the end of full-term deliveries. Mononuclear cells were isolated using a Ficoll-Hypaque (density, 1.077; Pharm acia Biotech, Upsala, Sweden) density gradient centrifugation. After two cycles of plastic adherence for 60 min, the cells were washed and suspended in PBS (phosphate buffered saline) (pH 7.4), which contained 0.1% bovine serum albumin. During these procedures, all adherent cells were removed and only nonadherent cells were recovered. The CD34 + cell fraction was isolated with a superparamagnetic microbead selection using monoclonal antibody (QBEND10) and miniMACS columns (Miltenyi Biotec; Bergisch Gladbach, Germany) (Kim, 2003) . The efficiency of purification and immunophenotype were verified with flow cytometry and counterstained with a FITC-anti-human CD34 (HPCA-2; Becton Dickinson; Mountain View, California) as previously described (Yoo et al., 1999) .
Ex vivo expansion of CD34
+ hem atopoietic stem cells CD34 + cells were placed into 24-well plates (Falcon; Becton Dickinson Biosciences) at a concentration of 1×10 3 cells per well. Each well contained 0.5 ml liquid medium plus the growth factors of interest. The culture medium consisted of Iscove's modified Dulbecco's medium (IMDM; Gibco BRL) supplemented with 10% fetal bovine serum. The cytokines included recombinant human G-CSF (100 U/ml), TPO (10 U/ml), and FL (50 ng/ml). The cultures were incubated at 37 o C in a humidified atmosphere containing 5% CO2. On day 14, cells were harvested from the culture and the number of viable cells was determined by trypan blue exclusion. Cell counts were also performed using a hemocytometer. The cells from these aliquots were assayed for the number of hematopoietic progenitor cells. Apoptosis assay was performed using Annexin-V-Flous staining kit (Roche) following the manufacturer's protocol.
Clonogenic assays
Clonogenic assays were performed as follows: 1× 10 3 CD34 + UCB cells were cultured at two plates per point in complete methylcellulose medium (HCC-4434; Methocult; Stem Cell Technologies, Vancouver, Canada). It was supplemented with 50 ng/ml stem cell factor (SCF), 10 ng/ml interleukin-3, GM-CSF, and 1 U/ml recombinant human erythropoietin (EPO) at 37 o C in a humidified atmosphere at 5% CO2. After 14 days of incubation, colonies were enumerated with the aid of an inverted microscope and counted by morphologic criteria.
Reverse transcription (RT)-PCR
Total cellular RNA was extracted from HSCs and dissolved in DEPC (diethylpyrocarbonate)-treated water. One microgram of the extracted RNA was reverse transcribed into cDNA and amplified to determine both BLT2 and GAPDH mRNA expression according to manufacturer's protocol (Reverse-iTTM One-Step RT-PCR Kit; ABgene). Primers for human BLT2 are 5'-AGCCTGGAGACTCTGACCGCTTTCG-3' (forward) and 5'-GACGTAGAGCACCGGGTTGACG-CTA-3' (reverse) (Tong et al., 2002) . Primers for GAPDH are 5'-CTGCACCACCAACTGCTTAGC-3' (forward) and 5'-CTTCACCACCTTCTTGATGTC-3' (reverse). 
Data analysis and statistics
The results are presented as the mean ± SD of the data obtained from three or more experiments performed in duplicates. Statistical comparisons between groups were made with the Student's t-test. Values of P 0.05 were considered significant.
R esults LTB 4 induces proliferation of C D 34 + HSCs
The effect of LTB4 on the in vitro proliferation of CD34 + hematopoietic progenitor cells from freshly purified UCB CD34 + cells was assessed using trypan blue exclusion assay. Earlier report of optimal culture condition for hematopoietic stem cells with combined supplementation of G-CSF, TPO and FL (Yoo et al., 1999) was used as a control culture and compared with the additional supplementation of LTB4. In the absence of exogenous cytokines, no viable cells were observed after 2 weeks of culture, regardless of whether or not LTB4 was present (data not shown). When mixture of G-CSF, TPO, and FL was added to the medium, the number of total cells was increased approximately 350 folds during the culture as expected (data not shown). Addition of LTB4 (300 nM) significantly enhanced the growth of CD34
+ HSCs approximately by 1.5 fold when compared to the condition where no LTB4 was added ( Figure 1A ). The effect of LTB4 was abolished by the addition of CP105696 (10 µ M), an antagonist of LTB4 receptors (BLT) ( Figure 1A) , suggesting the specific effect of LTB4 on the proliferation of CD34 + hematopoietic stem cells.
LTB4 exerts anti-apoptotic effect on CD34
+ hem atopoietic stem cells LTB4 was reported to be involved in cell survival by its anti-apoptotic effect on various cells such as neutrophil (Hebert et al., 1996; Zhang et al., 2002) . We performed Annexin-V staining to determine whether LTB4 exerts anti-apoptotic effect also on CD34 + HSCs in a long term culture. As seen in Figure 2 , addition of LTB4 decreased apoptosis when compared to the control and CP105696 treatment inhibited the anti-apoptotic effect of LTB4 statistically significantly (P 0.05). These results suggest that the growth advantage of LTB4 on HSC is, at least partly, due to its anti-apoptotic effect.
LTB4 induces differentiation of CD34 + HSCs
After 2 weeks of ex vivo expansion, purity of CD34 + HSCs was assesed by flow cytometry using CD34 antibody. Interestingly, the results were opposite to the growth experiments, where treatment of LTB4 showed lowest purity of HSCs in terms of retention of CD34 ( Figure 1B) . Accordingly, addition of BLT antagonist showed highest CD34-positive populations ( Figure 1B) . The fact that the specific antagonist increased the purity of CD34 + HSCs even in the absence of LTB4 might be due to the blockade of interaction between BLT and the endogenously produced LTB4 during differentiation of CD34 + HSCs (Spanbroek et al., 2000) . These results suggest that LTB4 induces differentiation of HSCs through its receptor during ex vivo expansion by autocrine or paracrinic manner, since the cells that lost CD34 might be differentiated or at least differentiating cells. Thus, we next performed clonogenic assays with methylcellulose cultures to confirm the involvement of LTB4 in HSC differentiation. In the methylcellulose cultures, addition of LTB4 yielded approximately twofold increase in colony formations of CFU-GM and CFU-GEMM, when compared to the condition where no LTB4 was added ( Figure 1C) . Again, this effect was inhibited by the addition of BLT antagonist, CP105696 (10 nM). In contrast, no significant differences in BFU-E-derived colony formation were observed in the presence or the absence of LTB4 or CP105696 ( Figure 1C ). Taken together, these results suggest that LTB4 may induce differentiation of CD34 + HSCs by its receptor-mediated interaction. 
Blockade of LTB 4 pathw ay induces self-renew al of CD34 + HSCs
From the above results, we assumed that it might be possible that self-renewal of CD34 + HSC can be increased by blocking LTB4-BLT interaction. Thus, we next determined the effect of BLT antagonist on selfrenewal of CD34 + HSCs. After two weeks of ex vivo expansion, the cultures were collected and run through the MACS column as mentioned above. After purification of CD34 + cells, number of the cells was assessed by trypan blue exclusion. As expected, treatment of CD105696 (10 µ M) increased number of CD34 + HSCs by approximately two-fold, compared to the control, whether LTB4 was added or not ( Figure  3A) . Even though there might be loss of a small portion of the cells during the purification, this result showed the similar tendency with absolute number of CD34 + cells ( Figure 3B ) calculated from total number of the cells ( Figure 1A ) and the purity of CD34 + HSCs ( Figure 1B) , confirming blockade of BLT induces proliferation of CD34 + HSCs. Since these CD34 + cells retained differentiating capacity as measured in clonogenic assays using methyl cellulose medium (data not shown), blockade of BLT may induce not only the proliferation but also the self-renewal of CD34 + HSCs.
Expression of BLT2, a receptor for LTB 4 , is induced during differentiation of CD34 + HSCs
The induced expression of BLT1 during the cytokineinduced differentiation of CD34 + stem cells was reported by Pettersson et al. (2003) . We next performed RT-PCR with BLT2-specific primers to investigate whether expression of BLT2, another receptor for LTB4 is also related to in vitro differentiation of CD34 + HSCs. As seen in Figure 4 , BLT2 expression was increased during the long term culture when the cytokines were added in the presence or absence of LTB4. However, the expression was decreased when the LTB4 receptor antagonist was treated. Taken together with previous report, these results show the expression of BLT maybe directly or at least indirectly related to the effect of LTB4 on HSCs' proliferation, survival, differentiation and self-renewal.
D iscu ssio n
Maintaining self-renewal and differentiation potential of hematopoietic stem cell (HSC) is a crucial component and a major challenge in stem cell research and potential clinical applications for HSC ex vivo expansion including tumor cell purging, gene therapy, and stem cell transplantation. In the present study, effects of LTB4 and its receptor on ex vivo expansion, differentiation and self-renewal of hematopoietic stem cells were determined.
LTB4 has been reported to enhance growth of a variety of cells including human pancreatic cancer cells (Tong et al., 2002) , and fibroblast (Woo et al., 2002) . In addition, various cytokines, evaluated for their ability to support human HSC long-term ex vivo expansion, share many common characteristics with LTB4, such as proinflammatory effects, chemotactic activities and growth-stimulating factors, and suggests that LTB4 might also be involved in the proliferation phase of HSCs.
In our study, LTB4 itself was unable to induce proliferation of HSC in the absence of other cytokines or even in the presence of any one or two combinations of three cytokines used in this study (data not shown). This is consistent with previous report where LTB4 had no effect on proliferation of CD34 + HSCs in the absence of any cytokines (Desplat et al., 2000) . However, when LTB4 was added to the culture medium supplemented with all three cytokines including G-CSF, TPO and FL, the growth of HSCs was increased by approximately 50%, compared to the control. Thus, mechanism of LTB4 in HSC proliferation is not solely due to self-mediated action but due to the concerted actions of other cytokines. For example, the cytokines might activate LTB4 signaling pathway or induce the expression of the proteins involved in LTB4 signaling. Certain cykokines such as IL-13 upregulates leukotriene receptor in human lung fibroblast (Chibana et al., 2003) . Indeed, the expression of BLT2, a LTB4 receptor, was induced during ex vivo expansion of HSCs in the presence of the cytokines (Figure 4) , suggesting the cytokines might up-regulate the expression of BLT2, directly or indirectly. Interestingly, the treatment of BLT2 antagonist induced down-regulation of the BLT2 itself expression implicating autocrine regulation of the receptor expression.
Several eicosanoids, including prostaglandins and leukotrienes, have been reported to regulate cellular differentiation and apoptosis (Rudolph et al., 2001) . Our results also showed anti-apoptotic effect of LTB4 on HSCs, suggesting the increase of the number of HSCs in the long term culture by LTB4 is, at least in part, due to the retardation of apoptosis. Even though the total cell number was increased, population of CD34 positive cells in LTB4-treated cells was lower than that of control. However, when the LTB4 receptor antagonist was treated, retention rate of CD34 was even higher than that of control, suggesting LTB4 induces differentiation of HSCs during ex vivo expansion. This was confirmed by the clonogenic assay, where LTB4 treatement enhanced differentiation of HSC into various hematopoietic progenitors including CFU-GM and CFU-GEMM. The fact that absolute number of CD34-positive cells was higher when the HSCs were treated with BLT antagonist, even though the total cell number was relatively lower, suggests that the regulation of LTB4 signaling pathway may contribute to the self-renewal as well as differentiation of HSCs. Taken together, LTB4-BLT interaction is closely related to the cytokines-induced hematopoeitic stem cell proliferation, differentiation, and self-renewal, and it might be possible to determine the stem cell fate as needed, i.e. towards self-renewal or differentiation, during ex vivo expansion by controlling LTB4-BLT2 signaling pathway.
Stem cells can be used to treat a variety of diseases and several recent studies in animal models demonstrate the potential of bioengineering strategies targeting adult and embryonic stem cells. In order to obtain the desired cells for transplantation, stem cell bioengineering approaches involve the manipulation of environmental signals influencing cell survival, proliferation, self-renewal and differentiation. In that regard, even though the exact mechanisms are still to be elucidated, our findings will facilitate the studies and the clinical applications in the field of the stem cell-based regenerative therapies, as treatment accessibility will depend on the development of powerful technologies to produce sufficient cell numbers. 
